Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patients.
Fiche publication
Date publication
avril 2022
Journal
Journal of cachexia, sarcopenia and muscle
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier, Dr SCHOTT Roland, Dr BENDER Laura, Pr FAVRET Fabrice, Pr GENY Bernard, Dr HUCTEAU Elyse, Dr MALLARD Joris
Tous les auteurs :
Mallard J, Hucteau E, Charles AL, Bender L, Baeza C, Pélissie M, Trensz P, Pflumio C, Kalish-Weindling M, Gény B, Schott R, Favret F, Pivot X, Hureau TJ, Pagano AF
Lien Pubmed
Résumé
Chemotherapy is extensively used to treat breast cancer and is associated with skeletal muscle deconditioning, which is known to reduce patients' quality of life, treatment efficiency, and overall survival. To date, skeletal muscle mitochondrial alterations represent a major aspect explored in breast cancer patients; nevertheless, the cellular mechanisms remain relatively unknown. This study was dedicated to investigating overall skeletal muscle mitochondrial homeostasis in early breast cancer patients undergoing chemotherapy, including mitochondrial quantity, function, and dynamics.
Mots clés
Apoptosis, H2O2, Mitochondrial biogenesis, Mitochondrial dynamics, Mitophagy, Skeletal muscle deconditioning
Référence
J Cachexia Sarcopenia Muscle. 2022 Apr 4;: